Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFECT: Afatinib with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT02975141Phase 1Unknown
- Sponsor
- Volker Heinemann
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afatinib in pancreatic adenocarcinoma (PDAC), sponsored by Volker Heinemann. Status: unknown.
02
Drugs
afatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02975141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975141.